Titan Pharmaceuticals
TTNP
$6.88
Share price
-2.55%
Change (1 day)
805.26%
Change (1 year)
Categories
P/S ratio for Titan Pharmaceuticals (TTNP)
P/S ratio as of May 2024 (TTM): > 1000
According to Titan Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6125.37. At the end of 2023 the company had a P/S ratio of > 1000.
P/S ratio history for Titan Pharmaceuticals from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | > 1000 | 3209.2% |
| 2022 | 188 | 2318.04% |
| 2021 | 7.77 | 57.97% |
| 2020 | 4.92 | 59.41% |
| 2019 | 3.08 | 4.75% |
| 2018 | 2.94 | -97.75% |
| 2017 | 131 | 2221.59% |
| 2016 | 5.63 | -89.44% |
| 2015 | 53.3 | 282.3% |
| 2014 | 13.9 | 172.01% |
| 2013 | 5.13 | -55.91% |
| 2012 | 11.6 | -30.14% |
| 2011 | 16.6 | 138.23% |
| 2010 | 6.99 | -99.59% |
| 2009 | > 1000 | 105.56% |
| 2008 | 829 | -40.75% |
| 2007 | > 1000 | -65.33% |
| 2006 | > 1000 | 672.28% |
| 2005 | 523 | -52.76% |
| 2004 | > 1000 | 326.52% |
| 2003 | 259 | 1798.05% |
| 2002 | 13.7 | -76.96% |
| 2001 | 59.3 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.88 | -99.94% | 🇺🇸 USA |
 Novartis NVS | 3.98 | -99.94% | 🇨🇭 Switzerland |
 Vanda Pharmaceuticals VNDA | 1.40 | -99.98% | 🇺🇸 USA |
 Repligen
RGEN | 14.5 | -99.76% | 🇺🇸 USA |
 MediciNova MNOV | 67.7 | -98.90% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 391 | -93.61% | 🇺🇸 USA |